Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner.

NPJ precision oncology·2026
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Author Correction: Community benchmarking and evaluation of human unannotated microprotein detection by mass spectrometry based proteomics.

Nature communications·2026
Same author

Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Expanding the human proteome with microproteins and peptideins.

Nature·2026
Same author

TCA cycle rewiring underpins histone acetylation sourcing and cell-fate transitions during exit from naive pluripotency.

Cell stem cell·2026

相关实验视频

Updated: Jul 24, 2025

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

9.9K

通过树突细胞重编程恢复瘤免疫性.

Olga Zimmermannova1,2, Alexandra G Ferreira1,2,3,4, Ervin Ascic1,2

  • 1Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, BMC A12, 221 84 Lund, Sweden.

Science immunology
|July 7, 2023
PubMed
概括
此摘要是机器生成的。

将癌细胞重新编程成抗原呈现细胞 (瘤APC) 可以增强免疫识别和抗瘤反应. 这种使用转录因子PU.1,IRF8和BATF3的新型免疫疗法方法,在延缓瘤生长和改善存活率方面表现有前途.

更多相关视频

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

11.9K

相关实验视频

Last Updated: Jul 24, 2025

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

9.9K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

11.9K

科学领域:

  • 免疫学 免疫学 免疫学
  • 癌症生物学 癌症生物学
  • 细胞重编程 细胞重编程

背景情况:

  • 癌细胞逃避免疫检测,部分原因是抗原呈现减少.
  • 树突细胞对于启动针对瘤的适应性免疫反应至关重要.

研究的目的:

  • 将癌细胞重新编程成专业的抗原呈现细胞 (瘤APC).
  • 研究瘤APC在癌症免疫治疗中的治疗潜力.

主要方法:

  • 利用了1型常规树突细胞 (cDC1) 的最小基因调节网络.
  • 在36个癌细胞系中强制表达转录因子PU.1,IRF8和BATF3 (PIB).
  • 在重编程瘤APC中评估了转录,表观遗传和功能变化.

主要成果:

  • 重编程诱导cDC1表型,恢复抗原呈现复合体和共刺激分子.
  • 瘤APC增强了MHC-I上的内源抗原呈现,激活了CD8+ T细胞.
  • 重编程的细胞显示瘤发生能力受损,瘤生长延迟,活体生存率增加.
  • 瘤APC与免疫检查点抑制剂显示出协同作用.

结论:

  • 将癌细胞重新编程成瘤APC是一种可行的策略,可以增强抗瘤免疫力.
  • 这种方法为开发针对内源性瘤抗原的新型免疫疗法提供了一个平台.
  • 瘤APC可以从血液和固体瘤产生,包括人类初级细胞.